Atsushi Kurihara

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS
    Enaksha R Wickremsinhe
    Eli Lilly and Company, Indianapolis, IN, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 932:117-22. 2013
  2. doi request reprint Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Bioanalysis 5:159-70. 2013
  3. ncbi request reprint Validating regulatory-compliant wide dynamic range bioanalytical assays using chip-based nanoelectrospray tandem mass spectrometry
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Rapid Commun Mass Spectrom 19:47-56. 2005
  4. ncbi request reprint Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 35:917-21. 2007
  5. doi request reprint Dried blood spot sampling: coupling bioanalytical feasibility, blood-plasma partitioning and transferability to in vivo preclinical studies
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, IN, USA
    Bioanalysis 3:1635-46. 2011
  6. doi request reprint Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement
    Enaksha R Wickremsinhe
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Anal Chem 82:6576-83. 2010
  7. doi request reprint Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans
    Nagy A Farid
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 50:126-42. 2010
  8. ncbi request reprint The disposition of prasugrel, a novel thienopyridine, in humans
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 35:1096-104. 2007
  9. ncbi request reprint Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
    Jessica L Fayer Rehmel
    Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, IN 46285, USA
    Drug Metab Dispos 34:600-7. 2006
  10. ncbi request reprint Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes
    Emi Kamiyama
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co, Ltd, Tokyo, Japan
    Drug Metab Pharmacokinet 22:267-75. 2007

Collaborators

Detail Information

Publications13

  1. doi request reprint High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS
    Enaksha R Wickremsinhe
    Eli Lilly and Company, Indianapolis, IN, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 932:117-22. 2013
    ....
  2. doi request reprint Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Bioanalysis 5:159-70. 2013
    ....
  3. ncbi request reprint Validating regulatory-compliant wide dynamic range bioanalytical assays using chip-based nanoelectrospray tandem mass spectrometry
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Rapid Commun Mass Spectrom 19:47-56. 2005
    ..This technology offers the possibility for increased throughput for studies supporting drug development by providing fast data turnaround for assays conforming to regulatory guidelines and GLPs...
  4. ncbi request reprint Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 35:917-21. 2007
    ..The ratios of the R-138727 stereoisomers were consistent among subjects, regardless of the dose or time of sample collection or whether the blood was sampled after the first dose or after 4 weeks of therapy...
  5. doi request reprint Dried blood spot sampling: coupling bioanalytical feasibility, blood-plasma partitioning and transferability to in vivo preclinical studies
    Enaksha R Wickremsinhe
    Lilly Research Laboratories, Eli Lilly and Company, IN, USA
    Bioanalysis 3:1635-46. 2011
    ..The adoption of dried blood spot (DBS) sampling and analysis to support drug discovery and development requires the understanding of its bioanalytical feasibility as well as the distribution of the analyte in blood...
  6. doi request reprint Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement
    Enaksha R Wickremsinhe
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Anal Chem 82:6576-83. 2010
    ..Results are presented which confirm that the ratio of dFdC to dG in DNA isolated from tumor cells incubated with dFdC increases with increased exposure to the drug and that dFdC can also be quantified from DNA extracted from blood...
  7. doi request reprint Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans
    Nagy A Farid
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 50:126-42. 2010
    ..Current literature shows that greater ADP-mediated IPA is associated with significantly better clinical outcomes for patients with acute coronary syndrome...
  8. ncbi request reprint The disposition of prasugrel, a novel thienopyridine, in humans
    Nagy A Farid
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 35:1096-104. 2007
    ..Total radioactivity was higher in plasma than in blood, suggesting limited penetration of prasugrel metabolites into red blood cells. Approximately 70% of the dose was excreted in the urine and 25% in the feces...
  9. ncbi request reprint Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
    Jessica L Fayer Rehmel
    Department of Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, IN 46285, USA
    Drug Metab Dispos 34:600-7. 2006
    ..These K(i) values exceed circulating concentrations in humans by 3.8- to 43-fold. Therefore, neither R-95913 nor R-138727 is expected to substantially inhibit the P450-mediated metabolism of coadministered drugs...
  10. ncbi request reprint Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes
    Emi Kamiyama
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co, Ltd, Tokyo, Japan
    Drug Metab Pharmacokinet 22:267-75. 2007
    ....
  11. ncbi request reprint Excitation and circular dichroism spectra of (-)-(3aS, 7aS)-2-chalcogena-trans-hydrindans(Ch = S, Se, Te): SAC and SAC-CI calculations
    Yasushi Honda
    Department of Chemistry, Graduate School of Science, Tokyo Metropolitan University, 1 1 Minami Osawa, Hachioji shi, Tokyo 192 0397, Japan
    J Comput Chem 29:612-21. 2008
    ..Our calculations predict the triplet states that account for the spectral shapes, indicating importance of the spin-orbit interaction effects for the accurate reproduction of the experimental spectra of the telluride...
  12. ncbi request reprint Tissue distribution of humanized anti-human Fas monoclonal antibody (R-125224) based on fas antigen-antibody reaction in collagen-induced arthritis monkeys
    Motoko Saito
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co, Ltd, 1 2 58, Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Life Sci 80:2005-14. 2007
    ..51+/-0.08 and 0.60+/-0.11 nM, respectively, which were similar to those values in human lymphocytes and hepatocytes, demonstrating that R-125224 cross-reacts with the monkey Fas antigen...
  13. ncbi request reprint Brain insulin impairs amyloid-beta(1-40) clearance from the brain
    Takeshi Shiiki
    Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Company, Shinagawa ku, Tokyo 140 8710, Japan
    J Neurosci 24:9632-7. 2004
    ..In conclusion, the present study has demonstrated the involvement of a proteolytic degradation process and an insulin-sensitive process in cerebral Abeta(1-40) clearance in the rat...